GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (NAS:REGN) » Definitions » Pre-Tax Income

Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Pre-Tax Income : $4,199 Mil (TTM As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Regeneron Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Regeneron Pharmaceuticals's pretax income for the three months ended in Dec. 2023 was $1,148 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $4,199 Mil. Regeneron Pharmaceuticals's pretax margin was 33.42%.

During the past 13 years, Regeneron Pharmaceuticals's highest Pretax Margin was 58.03%. The lowest was 27.00%. And the median was 36.22%.


Regeneron Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Regeneron Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Pre-Tax Income Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,429.10 3,810.40 9,325.80 4,858.80 4,199.30

Regeneron Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,324.70 858.00 1,082.90 1,110.80 1,147.60

Competitive Comparison of Regeneron Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Pre-Tax Income falls into.



Regeneron Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Regeneron Pharmaceuticals's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=4233.2+-456.8+-73+495.9+9.0949470177293E-13
=4,199

Regeneron Pharmaceuticals's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=1002.9+14.3+-18.3+148.7+0
=1,148

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $4,199 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regeneron Pharmaceuticals  (NAS:REGN) Pre-Tax Income Explanation

Regeneron Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pretax Income/Revenue
=1147.6/3434.3
=33.42%

During the past 13 years, Regeneron Pharmaceuticals's highest Pretax Margin was 58.03%. The lowest was 27.00%. And the median was 36.22%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regeneron Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals (Regeneron Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
Executives
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Arthur F Ryan director CITIZENS FINANCIAL GROUP, INC, 600 WASHINGTON BOULEVARD, STAMFORD CT 06901
George Yancopoulos director, officer: President and CSO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Huda Y Zoghbi director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Marion Mccourt officer: SVP Commercial C/O AXOVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018
Michael S Brown director
Christopher R. Fenimore officer: VP, Controller REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Andrew J Murphy officer: EVP Research REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Kathryn Guarini director 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
David P Schenkein director C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Van Plew Daniel P officer: EVP & General Mgr Industrial O REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Robert E Landry officer: SVP Fin, Dep CFO 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Christine A Poon director C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Neil Stahl officer: SVP, Preclinical Development 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
Joseph L Goldstein director DEPT OF PHARMACOLOGY K5 YUVER OF TEXAS, 5323 HARRY HINES BLVD, DALLAS TX 75390